Induced Proximity Molecules Market Set for Rapid Growth with Breakthrough Drug Discovery Innovations

Induced-proximity therapeutics have emerged as a significant modality in drug discovery, enabling the selective elimination of disease-causing biomolecules by harnessing endogenous degradation, which drives the growth of the market. 

What are Induced Proximity Molecules?

Induced-proximity drug discovery represents a shift from classical occupancy-driven pharmacology to approaches that control protein function by enforced protein–protein interactions. Continued innovation in these modalities is expected to significantly impact drug discovery by allowing selective and durable modulation of proteins earlier considered undruggable. Induced proximity is a significant approach for regulating proteins via loss or gain of function. This innovative mechanism employs proximity-inducing molecules to bring proteins or nucleic acids to modulate the function of a target and the related cellular technology. Major biotech companies have leveraged the therapeutic potential of the encouraged proximity strategy to develop drugs against several diseases.

Global Market Growth

The global induced proximity molecules market size was estimated at USD 4.2 billion in 2025 and is predicted to increase from USD 4.99 billion in 2026 to approximately USD 23.32 billion by 2035, expanding at a CAGR of 18.7% from 2026 to 2035.

Recent Advancements in Group-transfer Chimeras for Inducing Proximity:

Induced proximity has changed into a versatile platform with the potential to transform drug discovery. Scientists developed a novel strategy using molecules called Group-transfer chimeras for inducing proximity (GRIPs). Increasing the induced-proximity paradigm beyond proteins, researchers have recently developed small-molecule chimeras that target RNA for degradation. These are known RIBOTACs, heterobifunctional or multispecific molecules that bind an RNA of interest and concurrently recruit an RNase to cleave that RNA. GRIPs avert rebound signalling, initiate PTM crosstalk, and clear pathogenic PTMs in cellular systems.

Market Segmentation Overview

• By molecule type, the PROTACs segment contributed the largest U.S. induced proximity molecules market share of 52% in 2025, as PROTACs provide an adaptable strategy to degrade undruggable proteins, increasing the range of potential therapeutic targets. PROTACs overcome many of the limitations of small-molecule inhibitors, and they provide different benefits from the traditional concepts of drug discovery by targeted protein degradation. PROTACs have the strength to target the undruggable targets that limit conventional medicines.
• By target protein class, the kinases segment contributed the largest market share of 34%, as protein kinases, as one of the most significant human enzymes, are signalling molecules that regulate whole cell activities, involving growth, cell division, and metabolism. Kinases are significant in metabolism, cell signalling, cellular transport, protein regulation, secretory processes, and many different cellular pathways.
• By therapeutic area, the oncology segment contributed the largest U.S. induced proximity molecules market share of 58%, as induced proximity enables the targeting of proteins earlier considered untreatable because they lack functional binding pockets. These agents often form a steady ternary complex that offers high specificity for the target protein.
• By end user, the pharmaceutical & biotechnology companies segment contributed the largest market share of 68%, as proximity agents are developing modalities in biology and drug discovery. These transform the fate of a target and modulate related biological techniques by intentionally encouraging the proximity between a target and an effector protein. Induced proximity, which uses small molecules to drive an interaction between two proteins to harness natural biological ways, shows a revolution in synthetic chemistry and drug discovery.

Top Companies in the U.S. Induced Proximity Molecules Market

The top five companies in this group dominate the U.S. induced proximity molecules market. Meanwhile, Arvinas, the leader in PROTAC drug discovery, is taking the most advanced assets into clinical trials. C4 Therapeutics it is focusses in TPD to create novel medicines for cancer and neurodegenerative diseases. Monte Rosa Therapeutics (MA) is progressing precision medicine-based molecular glue degraders. Magnet Biomedicine, a molecular glue organization that evolved from stealth to expand the scope of glue medicines. Kayak Therapeutics, it develops covalent, induced proximity-driven therapies targeting E3 ubiquitin ligases.

Segments Covered in the Report

By Molecule Type

• PROTACs
• Molecular Glues
• LYTACs
• AUTACs & ATTECs

By Target Protein Class

• Kinases
• Transcription Factors
• Epigenetic Proteins
• GPCRs & Membrane Proteins
• Others

By Therapeutic Area

• Oncology
• Neurological Disorders
• Immunology & Inflammation
• Infectious Diseases
• Others

By End User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations (CROs)

By Stage of Development

• Preclinical
• Phase I
• Phase II
• Phase III & Commercial